烧伤患者碳青霉烯耐药革兰阴性菌菌血症:黏菌素单药与联合治疗比较
该回顾性观察研究纳入2014至2017年韩国首尔Hangang Sacred Heart Hospital烧伤ICU的84例碳青霉烯耐药革兰阴性菌菌血症患者,比较黏菌素单药(32例)与以黏菌素为基础的联合治疗(52例)的结局。两组7天清除率(71.9% vs 75.0%,P=0.752)和30天死亡率(31.2% vs 38.5%,P=0.503)均无显著差异。Cox回归显示Charlson合并症指数、使用黏菌素前肾脏替代治疗和抗生素疗程与30天死亡率相关。
要点
- 黏菌素单药与联合治疗在7天清除率和30天死亡率上无显著差异。
- Charlson合并症指数、使用黏菌素前肾脏替代治疗和抗生素疗程与30天死亡率相关。
- 联合治疗未显示微生物学和临床结局优势。
核心结论
- 以黏菌素为基础的联合治疗与黏菌素单药相比,在烧伤患者碳青霉烯耐药革兰阴性菌菌血症的微生物学和临床结局上无显著差异。
研究设计与样本
- 回顾性观察研究,2014至2017年于韩国首尔Hangang Sacred Heart Hospital烧伤ICU开展,纳入84例因创面感染导致碳青霉烯耐药革兰阴性菌菌血症的烧伤患者,其中黏菌素单药32例、以黏菌素为基础的联合治疗52例。
主要发现
- 7天清除率:单药组71.9%,联合治疗组75.0%,P=0.752。
- 30天死亡率:单药组31.2%,联合治疗组38.5%,P=0.503。
- Cox回归显示Charlson合并症指数与30天死亡率相关(HR 1.23;95%CI 1.02-1.49;P=0.030)。
- 使用黏菌素前肾脏替代治疗与30天死亡率相关(HR 2.28;95%CI 1.05-4.94;P=0.037)。
- 抗生素疗程与30天死亡率相关(HR 0.94;95%CI 0.89-0.99;P=0.042)。
临床怎么用
- 对于烧伤患者碳青霉烯耐药革兰阴性菌菌血症,黏菌素单药治疗可作为联合治疗的替代选择,无需常规联合用药。
- 应关注Charlson合并症指数高、使用黏菌素前需肾脏替代治疗的患者,其30天死亡风险较高。
局限性
- 回顾性观察研究,样本量较小(共84例),可能存在选择偏倚和混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Carbapenem-resistant gram negative pathogen (CR-GNP) infection in burn patients is a growing concern since treatment options are limited and resistance to the main line of treatment, colistin, is increasing. The goal of this study was to compare treatment outcomes of colistin monotherapy versus colistin-based combination therapy for CR-GNP bacteremia in burn patients. A retrospective observational study was conducted between 2014 and 2017 in Hangang Sacred Heart Hospital located in Seoul, South Korea. Among the burn patients admitted to the burn intensive care unit with CR-GNP bacteremia due to wound infections, colistin monotherapy or colistin-based combination therapy were investigated. We determined both eradication rate within seven days as well as mortality rate within 30 days. A total of 84 burn patients with CR-GNP bacteremia were analyzed-32 were treated with colistin monotherapy and 52 with colistin-based combination therapy. We found that eradication rate within 7 days and 30-day mortality rate were not significantly different between the two groups (71.9% versus 75.0%, P = 0.752 and 31.2% versus 38.5%, P = 0.503). In the Cox regression analysis, Charlson's comorbidity index, renal replacement therapy before colistin use, and duration of antibiotics were associated with 30-day mortality (HR, 1.23; 95% CI, 1.02-1.49; P = 0.030, HR, 2.28; 95% CI, 1.05-4.94; P = 0.037 and HR, 0.94; 95% CI, 0.89-0.99, P = 0.042, respectively). Colistin-based combination therapy did not show significant differences with regard to microbiologic and clinical outcomes compared with colistin monotherapy.
引用
- Park JJ, Seo YB, Lee J, et al. Colistin monotherapy versus colistin-based combination therapy for treatment of bacteremia in burn patients due to carbapenem-resistant gram negative bacteria. Burns. 2020. PMID: 32622621. doi:10.1016/j.burns.2020.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。